Last updated: July 11, 2026
TherapeuticsMD v. Teva (2:20-cv-03485): Litigation Summary, Patent Issues, and Generic Risk Analysis
Executive summary: In TherapeuticsMD, Inc. v. Teva Pharmaceuticals USA, Inc. (D. N.J., No. 2:20-cv-03485), TherapeuticsMD asserted Hatch-Waxman (35 U.S.C. § 271(e)(2)) patent infringement against Teva’s contemplated generic entry. The case posture and likely dispute focus is typical of Orange Book-driven Paragraph IV litigation: claims tied to listed patents for the reference drug, with Teva challenging infringement and/or invalidity and TherapeuticsMD seeking a preliminary injunction and a permanent finding of infringement.
Result and settlement terms are not provided in the available input, so no accurate case outcome or payment/licensing detail can be stated.
What is the case background for TherapeuticsMD v. Teva (2:20-cv-03485)?
Case caption and forum:
- Plaintiff: TherapeuticsMD, Inc.
- Defendant: Teva Pharmaceuticals USA, Inc.
- Court: U.S. District Court (District of New Jersey)
- Docket: 2:20-cv-03485
- Year filed: 2020
Legal posture (standard for this docket type):
- Filed as a Hatch-Waxman patent infringement action under 35 U.S.C. § 271(e)(2) following Teva’s submission to FDA (typically an ANDA with Paragraph IV certifications against Orange Book patents for the brand product.
Core dispute pattern in these cases:
- TherapeuticsMD theory: Teva’s proposed generic product would infringe one or more Orange Book-listed patents, either literally or under the doctrine of equivalents.
- Teva defenses: non-infringement, invalidity (anticipation/obviousness under § 102/§ 103, lack of written description/enablement under § 112), and sometimes unenforceability arguments tied to prosecution conduct.
What matters commercially:
- The case typically determines whether Teva is barred from launch until patent expiration or design-around, and whether the parties enter a settlement that links to a mutually agreed entry date.
Limitations: The provided input does not include the asserted patent numbers, the specific ANDA filing date, the Orange Book listing(s) at issue, the claim construction results, or the disposition (dismissal, summary judgment, trial judgment, or settlement). Without those, an accurate patent-by-patent litigation map cannot be produced.
Which patents were asserted in TherapeuticsMD v. Teva (2:20-cv-03485)?
Answer needed for accuracy: Identifying asserted patents requires the complaint or the court docket entries that list the specific patent numbers and claim charts.
Available input limitation: No complaint claims, patent list, or Orange Book numbers were included with the docket reference.
Common asserted patent categories in TherapeuticsMD/ANDA disputes
When TherapeuticsMD is the plaintiff in Hatch-Waxman actions, the asserted estate often includes one or more of the following clusters:
- Composition of matter (active ingredient and/or chemically defined product)
- Formulation patents (excipients, stability-enhancing compositions, controlled-release or delivery system)
- Method-of-use patents (indications, dosing regimens, patient subsets)
- Manufacturing method patents (process claims that can block generic manufacturing)
Not stated here: Which specific category or which specific patents were asserted in this docket.
What defenses did Teva raise in the TherapeuticsMD v. Teva Paragraph IV action?
Typical Paragraph IV defenses at this stage:
- Non-infringement
- Teva argues its proposed product does not meet one or more limitations in the asserted claims.
- Invalidity
- Anticipation and obviousness over prior art.
- Obviousness-type double patenting if relevant in the patent family.
- Indefiniteness / § 112 issues
- Lack of enablement or written description.
- Non-enforceability (less common but can arise)
- Inequitable conduct or prosecution-related defenses, depending on the factual record.
Not provided: The specific Teva invalidity theories and which references were cited in this particular case.
How does Hatch-Waxman exclusivity timing affect the settlement leverage in this case?
For Paragraph IV cases, exclusivity leverage flows from three time anchors:
1) Marketing exclusivity for the reference drug
- If the reference product has unexpired FDA exclusivity (3-year for new clinical investigations, 5-year for new chemical entity or pediatric exclusivity where applicable), Teva’s ANDA typically cannot be approved until those expire even if patents are invalid.
2) Patent expiry dates
- The main litigation driver is the earliest expiring asserted patent among the Orange Book listings at issue.
3) 30-month stay dynamics
- A timely Paragraph IV filing triggers a statutory 30-month stay of FDA approval if no earlier final court decision occurs.
Outcome dependency:
- If the court issues a final decision before the 30-month date, FDA approval timing becomes outcome-driven.
- If the case is dismissed or settles without an agreed date, the parties’ settlement terms dictate the practical launch window.
Not stated here: Exact patent expiry dates and whether exclusivity applied.
Did this case result in a preliminary injunction, dismissal, or final judgment?
Answer requires docket outcomes:
- A preliminary injunction would indicate the court found a likelihood of infringement and a likely validity bar sufficient to prevent launch.
- A dismissal or summary judgment for Teva would likely clear the path for FDA approval upon expiration of the stay or agreement terms.
- A settlement often includes a launch date and/or carve-outs (labeling, strength, dosage form, or claim-design-around).
Available input limitation: No judgment, order dates, or docket dispositions were included with the input.
What is the Orange Book status of the TherapeuticsMD drug(s) at issue?
Orange Book status is case-specific. It depends on:
- the reference listed drug (RLD) name
- the strength, dosage form
- the patent list and their expiration
- the Teva ANDA certification(s) (Paragraph IV vs other carve-outs like § 271(a)(2)/(a)(3) certifications)
Not provided: RLD name, strengths/dosage forms, or the Orange Book patent numbers tied to the asserted estate.
How strong is the patent estate asserted by TherapeuticsMD in this litigation?
Patent strength depends on:
- the remaining life of the asserted patents,
- claim scope breadth,
- litigation history of the same patents (e.g., survival in earlier cases),
- whether validity challenges have been sustained.
Available input limitation: Without the asserted patent list and the court’s validity analysis, a strength score would be speculative.
What generic entry risks existed for Teva after filing (and how were they mitigated)?
In Paragraph IV cases, generic entry risk is shaped by:
Key launch blockers
- pending asserted patents
- injunction risk
- unresolved appeal
- settlement non-performance risk
Typical mitigation instruments
- settlement agreement with defined entry date
- agreement to omit certain claims or strengths
- stipulations allowing launch only after a defined trigger
Not provided: Whether TherapeuticsMD and Teva entered a settlement and what launch date or restrictions applied.
What settlement terms are typical in TherapeuticsMD v. Teva-type litigations, and what applies here?
Typical settlement components (when present):
- payment or other value exchange (subject to antitrust scrutiny and disclosure requirements)
- agreed-at date for FDA approval and commercial launch
- covenants not to sue
- label and product design constraints
What applies here: Not determinable from the provided input.
How does this case compare with other TherapeuticsMD vs generic challenges (pattern-level analysis)?
At a pattern level, TherapeuticsMD’s enforcement strategy in Hatch-Waxman litigation generally tracks:
- asserting Orange Book patents tied to formulation, method of use, and/or compositions,
- targeting generics that file Paragraph IV certifications,
- pressing for entry delay through infringement findings and injunctive relief.
For this docket specifically: Patent numbers, product identity, and outcome are not included, so comparative assessment cannot be anchored in hard facts.
Key Takeaways
- Docket identity: TherapeuticsMD, Inc. v. Teva Pharmaceuticals USA, Inc., D.N.J., No. 2:20-cv-03485 is a Hatch-Waxman Paragraph IV patent litigation posture based on the plaintiff/defendant and filing year, consistent with Orange Book enforcement mechanics.
- Missing litigation specifics from input: The provided information does not include asserted patent numbers, product/RLD details, the court’s claim construction, validity rulings, or case disposition, preventing an accurate patent-by-patent infringement and strength analysis.
- Commercial impact mechanism: As with Paragraph IV cases, the dispute would determine whether Teva faced launch delay through injunction/stay outcomes or a settlement launch date, anchored to Orange Book patent expiries and FDA exclusivity.
FAQs
1) What is the procedural basis for TherapeuticsMD’s claim against Teva in 2:20-cv-03485?
It is framed as Hatch-Waxman patent infringement under 35 U.S.C. § 271(e)(2) tied to an ANDA Paragraph IV certification.
2) Does 2:20-cv-03485 involve an ANDA with Paragraph IV certifications?
The docket type is consistent with Paragraph IV Hatch-Waxman litigation, but the specific ANDA certification details are not included in the provided input.
3) What product and strength are at issue in this case?
Not provided in the input; product identity requires the complaint or docket exhibit naming the RLD/strength.
4) What patents were challenged for validity in this case?
Not provided; the patent numbers and invalidity grounds require complaint and claim/invalidity analysis not included in the input.
5) How would a settlement typically affect FDA approval and launch timing in Hatch-Waxman cases like this?
It usually sets a defined entry/launch date and may include labeling and covenant terms that govern FDA approval and commercialization.
References (APA)
- U.S. District Court, District of New Jersey. TherapeuticsMD, Inc. v. Teva Pharmaceuticals USA, Inc., No. 2:20-cv-03485 (2020).
